Cambrex Corporation (CBM)
(Delayed Data from NYSE)
$46.20 USD
+2.73 (6.28%)
Updated May 3, 2019 04:02 PM ET
After-Market: $46.20 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$46.20 USD
+2.73 (6.28%)
Updated May 3, 2019 04:02 PM ET
After-Market: $46.20 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Zacks.com featured highlights: Braskem S.A., Cambrex, FutureFuel and Gibraltar Industries
by Zacks Equity Research
Zacks.com featured highlights: Braskem S.A., Cambrex, FutureFuel and Gibraltar Industries
Juno Gets Breakthrough Therapy Status for Lymphoma Drug
by Zacks Equity Research
Juno Therapeutics, Inc. (JUNO) and partner Celgene Corporation (CELG), announced that the FDA has granted Breakthrough Therapy designation to their investigational candidate, JCAR017.
ACADIA Phase II Alzheimer's Drug Hits Primary Endpoint
by Zacks Equity Research
ACADIA Pharmaceuticals Inc. (ACAD) announced that a phase II exploratory study (-019 Study) evaluating pimavanserin for the treatment of Alzheimer's disease psychosis (AD Psychosis) met the primary endpoint.
4 Stocks Riding High on Increasing Cash Flow
by Zacks Equity Research
Achieving profit is no doubt a company's goal, but having healthy cash flow is imperative to its existence, development and success.
J&J Files for FDA Approval of Simponi Aria Label Expansion
by Zacks Equity Research
Johnson & Johnson's (JNJ), Janssen submitted two sBLAs in the U.S. seeking approval of Simponi Aria for the treatment of psoriatic arthritis and ankylosing spondylitis.
Biogen (BIIB) Board Okays Hemophilia Business Spin-off
by Zacks Equity Research
Biogen (BIIB) announced that its board of directors has approved the spin-off of its hemophilia business into a new company Bioverativ Inc.
Amgen Files for Approval of Osteoporosis Drug in Japan
by Zacks Equity Research
Amgen Inc. (AMGN) and partner UCB SA (UCBJF) announced that they have submitted an application seeking marketing approval for its investigational monoclonal antibody romosozumab to Japan's Pharmaceuticals and Medical Devices Agency (PMDA).
AbbVie (ABBV) Submits NDA for Next-Gen HCV Combo in US
by Zacks Equity Research
AbbVie Inc. (ABBV) announced that it has submitted a New Drug Application (NDA) to the FDA for its pan-genotypic regimen of glecaprevir/pibrentasvir (G/P).
Zacks.com featured highlights: Braskem SA, Cambrex, Gibraltar Industries, State National and Leucadia National
by Zacks Equity Research
Zacks.com featured highlights: Braskem SA, Cambrex, Gibraltar Industries, State National and Leucadia National
Conatus Stock Up on Liver Drug Collaboration with Novartis
by Zacks Equity Research
Conatus (CNAT) inked an exclusive option, collaboration and license agreement with Novartis (NVS) for the worldwide development and commercialization of emricasan.
Bet On These 5 Stocks with Striking Net Profit Margin
by Zacks Equity Research
There is no better metric than net profit margin when it comes to determining a company's profit level.
Pfizer Chantix Label Warning Lifted in U.S.; to Add New Data
by Zacks Equity Research
Pfizer, Inc. (PFE) announced that the FDA has lifted a boxed warning about neuropsychiatric side effects from the label of its smoking cessation drug, Chantix.
Zacks.com featured highlights: Coherent, Applied Materials, Cambrex, McDermott International and EnerSys
by Zacks Equity Research
Zacks.com featured highlights: Coherent, Applied Materials, Cambrex, McDermott International and EnerSys
Intercept (ICPT) Ocaliva Gains Conditional Approval in EU
by Zacks Equity Research
Intercept (ICPT) Ocaliva, in combination with UDCA, was approved in the EU for the treatment of PBC.
Zacks.com featured highlights: Applied Materials, Cambrex, Cirrus Logic, Daktronics and Seagate Technology
by Zacks Equity Research
Zacks.com featured highlights: Applied Materials, Cambrex, Cirrus Logic, Daktronics and Seagate Technology
7 Stocks Near 52-Week Highs to Buy Right Now
by Zacks Equity Research
Over the past few decades, trading got more challenging with a rising number of investment strategies flooding the markets.
Kite Pharma Enters into Partnership with Vitruvian Networks
by Zacks Equity Research
Kite Pharma (KITE) entered into a strategic partnership with Vitruvian Networks to create a software solution to support commercial availability of T-cell therapies.
Repros to Meet with the FDA for Phase III Proellex Program
by Zacks Equity Research
Repros (RPRX) announced that it has requested a meeting with the FDA to discuss requirements for phase III development of Proellex.
Novartis Offers Positive Data on Breast Cancer Drug LEE011
by Zacks Equity Research
Novartis (NVS) announced results from the phase III MONALEESA-2 study on LEE011 for the treatment of first-line HR+/HER2- advanced breast cancer.
Endo (ENDP) Inks Deal to Return Belbuca Rights to BioDelivery
by Zacks Equity Research
Endo (ENDP) announced that it has entered into an agreement to return the rights for Belbuca to BioDelivery (BDSI).
Zacks.com featured highlights: Big 5 Sporting Goods, Cambrex and Children's Place
by Zacks Equity Research
Zacks.com featured highlights: Big 5 Sporting Goods, Cambrex and Children's Place
AstraZeneca (AZN) Presents Tagrisso Data at Medical Meeting
by Zacks Equity Research
AstraZeneca plc (AZN) presented positive data from a randomized phase III study (AURA3) on its lung cancer drug Tagrisso at a lung cancer conference in Vienna, Austria.
Is Cooper Companies (COO) Poised for Earnings Beat in Q4?
by Zacks Equity Research
The Cooper Companies Inc. (COO) is set to report fourth-quarter fiscal 2016 results after the market closes on Dec 8.
Sage Therapeutics Stock Up on SAGE-547 Regulatory Update
by Zacks Equity Research
Sage (SAGE) announced expedited development plan on SAGE-547 following receipt of formal meeting minutes from a breakthrough therapy meeting with the FDA.
Juno Reports Positive Phase I Study Data on Lymphoma Drug
by Zacks Equity Research
Juno Therapeutics, Inc. (JUNO) announced encouraging preliminary clinical data from a phase I study (TRANSCEND) on its lead pipeline candidate, JCAR017, for the treatment of patients non-Hodgkin lymphoma (NHL).